Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review.
The FDA has accepted a new drug application for the selective estrogen receptor degrader, elacestrant, and granted it priority review for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer, according to an announcement by The Menarini Group.
The NDA is supported by findings from the phase 3 EMERALD study (NCT03778931), which met its co-primary end points of improving progression-free survival (PFS) in both the overall population and the ESR1 mutation-positive subgroup compared with standard of cancer endocrine monotherapy.
In the randomized, open-label, active-controlled study, approximately 477 patients were assigned to receive either oral elacestrant 400 mg once daily (n = 239) or standard-of care (SOC) endocrine monotherapy consisting of either intramuscular fulvestrant 500 mg, anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily (n = 238). In addition to PFS, the study investigated overall survival (OS) in the overall population and ESR1-positive subgroup as secondary end points.
At 12 months, the PFS among patients in the overall population who received elacestrant was 22.32% compared with 9.42% in the SOC arm (HR, 0.70; 95% CI, 0.55-0.88; P =.002). In the ESR1-positive population, the 12-month PFS among patients treated with elacestrant was 26.76%vs 8.19% for those who received SOC (HR, 0.55; 95% CI, 0.39-0.77; P = .0005). Treatment with elacestrant in the EMERALD study led to a 30% reduction in the risk of disease progression in the overall population and a 45% reduction in the ESR1-positive population.
Treatment-related adverse events occurred in 7.2% of the elacestrant arm vs 2.1% of the SOC arm. TRAEs lead to treatment discontinuation for 3.4% of patients in the elacestrant compared with 0.9% of those in the SOC arm. Any-grade nausea was observed in 35.0% of patients treated with elacestrant vs 18.8% of those who received SOC. Grade 3/4 nausea was seen in 2.5% of the elacestrant arm vs 0.9% of the SOC. Arm.
"The FDA’s acceptance of our NDA with Priority Review marks an important regulatory milestone for our company," commented Elcin Barker Ergun, chief executive officer of the Menarini Group, in a press release. "We look forward to working with the FDA during its review of this submission, which addresses a new potential therapeutic option for a major unmet need in the management of patients with advanced or metastatic breast cancer after resistance builds in the earlier lines of the treatment."
The FDA has set the Prescription Drug User Fee Act target action date for elacestrant to February 17, 2023.
REFERENCES:
Menarini Group’s elacestrant granted priority review by the U.S. FDA for patients with ER+/HER2- advanced or metastatic breast cancer. News release. The Menarini Group August 11, 2022. Accessed August 11, 2022. https://bit.ly/3BWHrqb
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More